Genome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas. However, the clinical and biological significance of such aberrations and their subclonal distribution are poorly understood. Here, we present the first genome-wide array based study of pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia (B-CLL) that uses the computational statistical tool OncoSNP. We show that quantification of the proportion of copy number alterations (CNAs) and copy neutral loss of heterozygosity regions (cnLOHs) in each sample is feasible. Furthermore, we (i) reveal complex changes in the subclonal architecture of paired samples at relapse compared with pre-treatment, (ii) provide evidence supporting an association between increased genomic complexity and poor clinical outcome (iii) report previously undefined, recurrent CNA/cnLOH regions that expand or newly occur at relapse and therefore might harbor candidate driver genes of relapse and/or chemotherapy resistance. Our findings are likely to impact on future therapeutic strategies aimed towards selecting effective and individually tailored targeted therapies.
INTRODUCTION
Genome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas.
1 --10 B-cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the Western World. 11, 12 It is characterized by a chronic relapsing course and the development of chemotherapy refractoriness, leading to death in a significant subset of patients. There is, therefore, a clinical need to develop novel treatment strategies that overcome chemotherapy resistance.
B-CLL can be subclassified according to immunoglobulin heavy chain variable gene sequence (IGHV) homology into 'mutated' or 'unmutated' cases, reflecting good or poor prognosis, respectively. B-CLL shares many of the molecular characteristics seen in other forms of cancer and recurrent copy number alteration (CNAs) with relevance to prognosis have been described, including trisomy of chromosome 12 (16%) and loss of chromosomal regions 17p13.1 (TP53; 7%), 13 --17 11q22.3 (ATM; 18%) 18 --19 and 13q14.3 (DLEU2 and/or miR-15a/16-1; 55%). 20 --30 In addition, single-nucleotide polymorphism (SNP) and comparative genomic hybridization arrays have allowed novel recurrent genomic abnormalities to be identified 31 --33 that have been linked to prognosis in B-CLL. 30,34 --38 Current models of cancer progression are based on the concept that tumors are subject to the Darwinian process of evolution and selection. 39, 40 Recent studies in acute lymphoblastic leukemia have provided pivotal insights into the complex sequence of events during leukemogenesis, showing that the initiating mutation is followed by CNAs that drive the emergence of frank leukemia. 39 --42 Together, these data imply that at least some CNAs/copy neutral loss of heterozygosity regions (cnLOHs) are likely to be involved in driving leukemia progression and therefore might contribute to relapse. This led us to hypothesize that subclones containing driver CNAs/cnLOHs would newly occur or expand in relapse samples compared with samples taken before treatment and would be recurrent within our patient cohort. In contrast, random passenger mutations would remain unchanged or decrease/disappear in paired pre-treatment/relapse samples and would not be observed recurrently in different patients within the cohort. If correct, then we would anticipate that the identification of driver genes within recurrent or emerging/expanding regions of CNA/cnLOH might, in the longer term, have the potential to inform the design of novel therapies aimed at treating relapsed B-CLL.
In the present study we tested our hypothesis by systematically tracking the presence and subclonal distribution of CNAs/cnLOHs in patients before treatment and at subsequent relapse. To achieve this, we used high-resolution SNP array technology. We chose the newly developed computational statistical tool OncoSNP 10 that provides quantitative measures of cell admixture on a per-SNP level. OncoSNP was selected in preference to other dedicated cancer tools for SNP array analysis, 43 --47 because our data were generated from samples at two time points only and our study was specific to B-CLL, where spatial heterogeneity (for example, samples biopsied from different parts of a tumor, metastases, etc) is not applicable (see Supplementary Information, online). Furthermore, we were interested not only in the accumulation of genomic aberrations over time, but also particularly in the expansion of distinct subclones. Thus, OncoSNP best suited our study where (i) samples differed from solid tumors in being generally diploid with comparatively fewer CNAs (ii) normal cell contamination could be minimized and (iii) we had a specific interest in subclonal evolution.
PATIENTS AND METHODS
For a detailed account of the Materials, Patients and Methods used in this study please refer to the Supplementary Information online.
Patients and samples All patients gave written informed consent in accordance with the Declaration of Helsinki. In all, 135 samples from 93 patients were included in our cohort. For 42 of the 93 patients, paired pretreatment and relapse samples were available. Only samples from patients with lymphocytes contributing 490% of the total white blood cell count were included in the analysis. DNA was extracted from vital frozen cells using the QIAamp DNA Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
Fluorescence in situ hybridization (FISH) Interphase cells from CLL cultures were analyzed by FISH using the Vysis CLL FISH panel probe set (Abbott Molecular, Illinois, IL, USA) according to manufacturer's instructions.
Arrays
Hybridization to Illumina Genome-wide SNP chips was performed according to manufacturer's protocols found on registration at http://www.illumina.com/products/human1m_duo_dna_analysis_ beadchip_kits.ilmn and at http://www.illumina.com/support/array/ array_kits/humanomni1-quad_beadchip_kit/documentation.ilmn. The data were processed using GenomeStudioV2009.2 (Illumina, Inc., San Diego, CA, USA) and then analyzed using OncoSNP v1.0 (see below). For visual comparisons, the data were processed also using Nexus 5 Discovery Edition (BioDiscovery, Inc., El Segundo, CA, USA).
OncoSNP analysis Detailed methods have been described previously 10 and further details are given in the Supplementary Information online. To help identify and exclude germline CNVs of unlikely relevance from our data, we excluded SNP and monomorphic copy number probes in known germline CNV regions from the OncoSNP analysis and we also made use of the database of genomic variants 48 and the Wellcome Trust Case Control Consortium cohort data (see www.wtccc.org.uk). TP53 mutation analysis TP53 was screened for mutations using four high-resolution melting assays covering exons 5 --8. Following high-resolution melting, results were analyzed on the high-resolution melting module of the Corbett Rotor-Gene 6000 software 1.7 (available for download from QIAGEN, http://www.qiagen.com/corbett/support/ default.aspx). Positive PCR products were purified and then sequenced from both strands on the CEQ 8000 (Beckman Coulter, Fullerton, CA, USA).
IGHV mutation analysis
To identify clonal rearrangements of the IGHV gene and determine the somatic mutation status of the variable (V) gene sequence in patients we used the IGH Somatic Hypermutation Assay v2.0 (Invivoscribe, La Coutat, France) according to the manufacturer's instructions.
RESULTS
A flowchart outlining the patient numbers and overall study design is given in Supplementary Figure 1 Table 3 and Figure 4 online).
Genome-wide analysis of pre-treatment samples For our main study, we focused initially on the analysis of pretreatment samples from 93 patients undergoing regular follow-up at our institutions. This cohort was representative of CLL cohorts with a higher proportion of unmutated IGHV genes and/or treatment resistant cases that are referred to tertiary centers for treatment consideration ( We identified 58 previously unreported recurrent CNAs/cnLOHs (Table 2 ) (see Supplementary Information online for recurrence criteria). We established the minimally deleted regions (MDRs)/ minimally overlapping regions (MORs) of the recurrent CNAs/ cnLOHs and revealed interesting candidate genes including those implicated in B-cell maturation (for example, BLIMP1, NFkB2, TLR4, and CREBBP), tumor progression (for example, RND3, RHOT1; RHDBL; RAB20, and TRAP1), DNA damage response (for example, RIF1, TP53, ATG4D, and ATG5), tumor suppression (for example, NMI, CNOT7, PDGFRL, FGF20, PI3 K, and FOG2) and familial CLL (for example, SP140L, SP100) ( Table 2 ). Figure 1 shows examples of four of these novel recurrent regions of interest that span only a few candidate genes, potentially facilitating the identification of driver mutations. Sequencing of the TP53 gene, the known candidate underlying poor prognosis on 17p13.1, revealed mutations in 14 out of 93 patients and deletions in 11. However, exon sequencing of two of the emergent candidates, BLIMP1 and ATG5 revealed no mutations in 40 patients.
In order to establish the clinical significance of our findings, we correlated our array results with measures of clinical prognosis and risk, including IGHV mutation status and clinical risk scores defined by necessity for treatment intervention, progression free survival and chemotherapy resistance (see Supplementary Information, online). Genomic complexity was defined either by the presence of three or more CNAs X20 kb and/or cnLOHs X2 Mb in addition to, or other than, the known CNA regions assayed routinely by FISH, or by a total length of CNAs X5 Mb. Within the 93 pre-treatment samples, patients with unmutated IGHV genes showed a statistically significant higher total number of CNAs/ cnLOHs (50.0% X3 CNAs/cnLOHs) than patients with mutated IGHV genes (16.0% X3 CNAs/cnLOHs) (Cochran --Armitage trend exact test, P-value ¼ 0.0032, Supplementary Table 4 online) and patients with del17p/TP53 mutation showed a higher total length of CNAs/cnLOHs (90.9% 45 Mb CNAs/cnLOHs) (Cochran --Armitage trend exact test, P-value ¼ 0.0081, Supplementary Table 5, online).
In our small cohort, large Type II 13q deletions were not associated with a worse clinical outcome (Supplementary Tables 6 and 7 online) .
Furthermore, patients with high clinical risk scores had a higher number of CNAs/cnLOHs than patients with low clinical risk scores (Kruskal --Wallis test, P-value ¼ 0.0016) and showed a greater overall length of CNAs/cnLOHs than patients with low clinical risk scores (Kruskal --Wallis test, P-value ¼ 0.0002) (Supplementary Table 8 , online). Importantly, 16 patients had X3 CNAs/cnLOH but no 17p13.1 or 11q22.3 loss and would not have been picked up by FISH as a poor risk group.
Genome-wide comparison of paired pre-treatment/relapse samples Next, we focused on the analysis of the 42/93 patients for whom paired samples (that is, both pre-treatment and relapse samples) were available (Table 3) . We hypothesized that in addition to recurrent CNAs, newly occurring or expanding genomic aberrations would also represent potential drivers of disease progression. The percentages of subclones carrying CNAs/cnLOH regions were calculated from the SNP data using OncoSNP. 10 Only one case with mutated IGHV genes (CLL086) had additional CNAs at relapse. The other changes were percentage changes of preexisting CNAs. By contrast, 11 unmutated IGHV genes cases had complex evolution with emergence of one or more additional CNAs. When we looked at total length of CNAs/cnLOHs, patients without clonal evolution showed a statistically significant lower total length of CNAs/cnLOHs (58.8%o1 Mb) than patients with clonal evolution (68.0% 45 Mb)(Cochran --Armitage trend exact test, P-value ¼ 0.0075; Supplementary Table 9, online).
All 13q14.3 deletions were present before treatment and of the 21 patients manifesting these; seven exhibited X10% changed proportions of subclones carrying the deletion at relapse. In two cases, (CLL081 and CLL107), the proportion of subclones with the del13q14.3 appeared decreased at relapse and both exhibited additional CNAs elsewhere in the genome. For another two cases (CLL080 and CLL096), with deletions 41 Mb, the proportion of subclones with the 13q14.3 deletion had increased over time; both had isolated chromosome 13 anomalies ( Figure 2 ). Furthermore, in CLL071 and CLL080, there was extension of the 13q13.4 deletion in one allele (Supplementary Figure 6 online, Supplementary Table 5 ). Overall, the results suggest that extension of the deleted 13q14.3 locus may confer a clonal survival advantage in the minority of cases without additional CNAs/cnLOHs. By contrast, for patients with complex genomic aberrations, clones containing del13q14.3 are outcompeted.
Patients with del17p13.1/TP53 mutations were most likely to acquire additional CNAs at relapse (5/5). In addition, three patients without del17p13.1 at diagnosis developed del17p and other CNAs at relapse (CLL084 and CLL108, CLL145). Patient CLL081 was a clear example of this, manifesting a 17p13.1 deletion and multiple other CNAs pre-treatment. At the time of relapse, five CNAs had altered in proportion ( Figure 3 ) and two events (del2q33.1-q37.1 and del16p13) were newly identified. Furthermore, a number of the CNAs identified encompassed newly identified MDRs/MORs (Table 1) and included the genes LDB-1 and NFkB2 (10q24.32 MDR), SP140L and SP100 (2q37.1 MOR) and BTBD12, DNASE1, TRAP1 and CREBBP (16p13.3 MDR). Finally, the OncoSNP feature of defining proportions of subclones carrying CNAs/cnLOHs allowed us to use data from matched pre-treatment and relapse samples to infer likely subclonal populations and to map their evolutionary relationships. Schematic representations of the likely clonal architecture at different time-points for patients CLL081 and CLL106 are shown in Figure 4 with a further example for CLL092 in Supplementary Figure 7 online. These illustrate clearly a non-linear, branching subclonal hierarchy in B-CLL with multiple ancestral subclones, already present in pre-treatment samples and contributing to relapse. In conclusion, using the combination of high-resolution SNP array and OncoSNP, we were able to detect clonal evolution in 60% of treated patients with B-CLL. Interestingly, when comparing the regions affected by clonal expansion with recurrent regions we noticed a considerable overlap (Table 3 ). Many regions that were both recurrent and expanded or newly occurred in relapse samples included a very limited number of genes (Table 2, blue shading). These regions include genes that have a role in familial CLL (SP140L, SP100), in B-cell development and autophagy (BLIMP1 and ATG5, respectively) and FOG2, a regulator of phosphatidylinositol 3-kinase, which is None noted involved in cancer proliferation and survival. A fourth region affects NFIB involved in the NFKB pathway and two genes of no obvious CLL related annotation (TYRP1, MPDZ). A further region included DNA repair genes (BTBD12, DNASE1), TRAP1, a mitochondrial chaperone and regulator of apoptosis, as well as CREBBP, a frequently mutated gene in B-cell lymphomas. When we performed pathway analysis of the 546 genes in the MDRs/MORs affected by recurrent and emerging/expanding CNAs, we identified 17 over-represented, statistically significant and independent pathways of which eight contained 55 cancerrelated genes (phagosome P-value ¼ 0.0024; apoptosis P-value ¼ 0.0079; small-cell lung cancer P-value ¼ 0.0232; prostate cancer P-value ¼ 0.0284; pancreatic cancer P-value ¼ 0.0355; chronic myeloid leukemia P-value ¼ 0.0414; wnt signaling P-value ¼ 0.0436; cell cycle P-value ¼ 0.0497) (see Supplementary Table 10 , online).
DISCUSSION
Our study is the first genome-wide array based analysis of CNAs/ cnLOHs that both characterizes and quantifies the proportion of subclones carrying genomic changes before treatment and at subsequent relapse in cancer. The results demonstrate that (i) many CNAs/cnLOHs in CLL are recurrent and therefore nonrandom events that expand over time owing to Darwinian selective pressure, (ii) selected genes identified in both wellrecognized and newly defined MDRs/MORs present plausible candidates for driving disease progression and include those involved in mature B-cell development, DNA damage response (DNA repair, apoptosis and autophagy), tumor progression and familial B-CLL; pathway analysis was consistent with this. The identification of genes in this way will be informative for focused sequencing strategies. (iii) In our cohort there is strong supportive evidence that genomic complexity is associated with poor risk disease. This adds strength to previous studies that indicated a link between genomic complexity or clonal evolution to survival in CLL. 30, 36, 38 (iv) OncoSNP is a powerful computational statistical tool that alters fundamentally our ability to investigate clonal architectures and tease apart complex clonal dynamics. Furthermore, our results demonstrate the importance of developing comparable algorithms for application to next generation sequencing data. Although it is likely that in the longer term array technology will be replaced by whole genome sequencing, this study contributes to our understanding of the significance of CNAs/cnLOH in cancer progression. Finally, our results do not support the existence of a single leukemia propagating cell population but instead, shed light on the considerable genomic heterogeneity of cells driving disease progression.
Clinically, the existence of multiple, genetically distinct, subpopulations that escape therapeutic intervention presents formidable challenges for the development of effective treatments for patients with relapsed refractory B-CLL. Therefore, detailed characterization of the molecular basis of the condition and elucidation of the underlying mechanisms of clonal diversity will be essential for future targeted selection of effective therapeutic agents.
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